Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14145
UPID:
KEAP1_HUMAN
Alternative names:
Cytosolic inhibitor of Nrf2; Kelch-like protein 19
Alternative UPACC:
Q14145; B3KPD5; Q6LEP0; Q8WTX1; Q9BPY9
Background:
Kelch-like ECH-associated protein 1 (KEAP1), also known as Cytosolic inhibitor of Nrf2 and Kelch-like protein 19, plays a pivotal role in oxidative stress response. It acts as a substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex, targeting NFE2L2/NRF2 for ubiquitination under normal conditions. Upon oxidative stress, KEAP1 undergoes modifications that inhibit its ligase activity, leading to NFE2L2/NRF2 accumulation and the activation of detoxifying enzymes.
Therapeutic significance:
Understanding the role of Kelch-like ECH-associated protein 1 could open doors to potential therapeutic strategies.